Filtered By:
Infectious Disease: Coronavirus
Drug: Aspirin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 113 results found since Jan 2013.

Prophylactic anticoagulants for non-hospitalised people with COVID-19
CONCLUSIONS: We found low- to moderate-certainty evidence from five RCTs that prophylactic anticoagulants result in little or no difference in major bleeding, DVT, need for hospitalisation, or adverse events when compared with placebo or no treatment in non-hospitalised people with COVID-19. Low-certainty evidence indicates that prophylactic anticoagulants may result in little or no difference in all-cause mortality when compared with placebo or no treatment, but moderate-certainty evidence indicates that prophylactic anticoagulants probably reduce the incidence of VTE and PE. Low-certainty evidence suggests that comparing...
Source: Cochrane Database of Systematic Reviews - August 17, 2023 Category: General Medicine Authors: Brena C Santos Ronald Lg Flumignan Vinicius T Civile Álvaro N Atallah Luis Cu Nakano Source Type: research

A case of ischemic stroke and transient thrombocytopenia in a young female following adenoviral vector-based COVID-19 vaccination: Was the association incidental or causal?
We report a 23-year-old healthy female who developed seizures, altered sensorium, and left hemiparesis, 20 days after receiving the first dose of adenoviral vector-based COVID-19 vaccine "Covishield™." The patient had transient thrombocytopenia. The D-dimer level was 2460 ng/mL. Magnetic resonance imaging (MRI) demonstrated occlusion of M2 segment of the middle cerebral artery and cerebral infarction. Platelet factor-4 antibodies level was normal. Treatment with aspirin and antiepileptic drugs resulted in a remarkable recovery. This is the first Indian case report of ischemic stroke and transient thrombocytopenia followi...
Source: Primary Care - January 9, 2023 Category: Primary Care Authors: Shweta Pandey Ravindra Kumar Garg Pooja Tripathi Hardeep S Malhotra Neeraj Kumar Source Type: research

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00299-5. doi: 10.1016/S2213-2600(22)00299-5. Online ahead of print.ABSTRACTBACKGROUND: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin for prevention of disease progression in community patients with COVID-19.METHODS: The ACT outpatient, open-label, 2 × 2 factorial, randomised, controlled trial, was done at 48 clinical sites in 11 countries. Patients in th...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Wadea M Tarhuni Mohamed Hassany Anna Kontsevaya William Harper Sanjib Kumar Sharma Patricio Lopez-Jaramillo Antonio L D Source Type: research

Myopericarditis in a Young Adult Secondary to COVID-19 Vaccination
We present the case of a healthy 29-year-old male with no significant medical history who presented with electrocardiogram findings consistent with pericarditis and elevated troponin levels, commonly seen in myocarditis, after receiving his second Pfizer-BioNTec vaccination for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The patient had significant clinical improvement shortly after receiving aspirin and colchicine and was discharged home with these medications. His laboratory findings returned to baseline less than 2 weeks after his illness. While this case highlights the importance of diagnosis, interve...
Source: Methodist DeBakey Cardiovascular Journal - July 20, 2022 Category: Cardiology Authors: Corbin G Walters Dev D Jaiswal Tom X Hu Steve S Kim Source Type: research

No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease
CONCLUSION: There was no evidence for an effect of low-dose aspirin for primary cardiovascular prevention in reducing severe COVID-19.PMID:35755854 | PMC:PMC9204394 | DOI:10.1002/rth2.12743
Source: Thrombosis and Haemostasis - June 27, 2022 Category: Hematology Authors: J érémie Botton Laura Semenzato Julie Dupouy Rosemary Dray-Spira Alain Weill Olivier Saint-Lary Mahmoud Zureik Source Type: research

Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis
ConclusionsThis meta-analysis found that aspirin use was associated with a reduction in mortality in patients with COVID-19 and not with an increased risk of bleeding.
Source: European Journal of Clinical Pharmacology - June 22, 2022 Category: Drugs & Pharmacology Source Type: research

Effect of Aspirin on the prevention of pro-thrombotic states in hospitalized COVID-19 patients: Systematic review
CONCLUSIONS: Aspirin as an antiplatelet and anti-inflammatory agent may reduce the mortality rates in hospitalized patients with severe COVID-19. Further observational studies are necessary to determine the effect of aspirin on the prevention of prothrombotic states in hospitalized COVID-19 patients. The study was registered in the Systematic Review Registration: PROSPERO (pending registration ID: 300515).PMID:35366783 | DOI:10.2174/1871525720666220401102728
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 3, 2022 Category: Cardiology Authors: Masoumeh Abdi Zahra Hosseini Fatemeh Shirjan Leila Mohammadi Sahel Shafiee Dolat Abadi Nilofar Massoudi Moein Zangiabadian Mohammad Javad Nasiri Source Type: research